NMP, a joint venture between Sumitomo Chemical Company and GE Healthcare, will assess the ability of Fuzionaire's F-18 radiolabeling platform in a feasibility study. Fuzionaire aims to apply its technology to create new radiopharmaceuticals that can aid in predicting and measuring patient response to cancer immunotherapy treatments, according to the companies.

Formed in 2019 as a joint venture of Fuzionaire Diagnostics and Japan Medical Isotope Technology Development, FRIT is working to develop and commercialize Fuzionare Dx's radiopharmaceutical technologies in Japan.